文献速递白血病

CEBPB/IL-1β/TNF-α正反馈环路驱动单核细胞白血病对维奈克拉和MDM2抑制剂的耐药

A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia.
PubMed 文献 · Blood · 2025-01-01

研究通过对原发患者样本的功能基因组数据分析发现,MDM2抑制剂idasanutlin与维奈克拉一样对单核细胞白血病(FAB亚型M4/M5)无效。机制上,M4/M5白血病细胞CEBPB升高促进单核分化、抑制CASP3和CASP6、上调MCL1、BCL2A1及IL-1/TNF-α/NF-κB通路,异常单核细胞产生IL-1和TNF-α从外源性保护白血病原始细胞。维奈克拉或idasanutlin与IL-1/TNF-α通路抑制剂联用在M4/M5 AML中显示协同细胞毒性。

要点

  • MDM2抑制剂idasanutlin与维奈克拉对FAB亚型M4/M5单核细胞白血病无效。
  • CEBPB升高通过抑制CASP3/CASP6、上调MCL1/BCL2A1及IL-1/TNF-α/NF-κB通路介导内源性耐药。
  • 维奈克拉或idasanutlin联合IL-1/TNF-α通路抑制剂在M4/M5 AML中显示协同细胞毒性。

核心结论

  • 研究揭示涉及CEBPB、IL-1/TNF-α和单核分化的可靶向正反馈环路,在M4/M5白血病中促进对维奈克拉和MDM2抑制剂的内源性与外源性耐药及药物诱导性保护。

研究设计与样本

  • 研究整合分析了原发患者样本的功能基因组数据,并探索了内在与外在耐药因素。

主要发现

  • 单核细胞白血病细胞表达升高的CEBPB,促进单核分化、抑制CASP3和CASP6、上调MCL1、BCL2A1及IL-1/TNF-α/NF-κB通路成员,从而对多种MDM2抑制剂、BH3模拟物和维奈克拉联合方案产生耐药。
  • M4/M5白血病中异常单核细胞产生升高的IL-1和TNF-α,促进单核分化并上调炎性细胞因子和受体,从外源性保护白血病原始细胞免受维奈克拉和MDM2抑制。
  • IL-1β和TNF-α仅增加CEBPB水平并保护M4/M5细胞免受这些药物作用,而不保护M0/M1白血病细胞。
  • 维奈克拉和idasanutlin处理诱导CEBPB及IL-1/TNF-α/NF-κB通路的代偿性上调,且不依赖于FAB亚型,提示药物诱导的代偿性保护机制。
  • 维奈克拉或idasanutlin与阻断IL-1/TNF-α通路的抑制剂联用在M4/M5 AML中显示协同细胞毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MDM2 inhibitors are promising therapeutics for acute myeloid leukemia (AML) with wild-type TP53. Through an integrated analysis of functional genomic data from primary patient samples, we found that an MDM2 inhibitor, idasanutlin, like venetoclax, is ineffective against monocytic leukemia (French-American-British [FAB] subtype M4/M5). To dissect the underlying resistance mechanisms, we explored both intrinsic and extrinsic factors. We found that monocytic leukemia cells express elevated levels of CEBPB, which promote monocytic differentiation, suppress CASP3 and CASP6, and upregulate MCL1, BCL2A1, and the interleukin (IL-1)/tumor necrosis factor alpha (TNF-α)/NF-κB pathway members, thereby conferring drug resistance to a broad range of MDM2 inhibitors, BH3 mimetics, and venetoclax combinations. In addition, aberrant monocytes in M4/M5 leukemia produce elevated levels of IL-1 and TNF-α, which promote monocytic differentiation and upregulate inflammatory cytokines and receptors, thereby extrinsically protecting leukemia blasts from venetoclax and MDM2 inhibition. Interestingly, IL-1β and TNF-α only increase CEBPB levels and protect M4/M5 cells from these drugs but not M0/M1 leukemia cells. Treatment with venetoclax and idasanutlin induces compensatory upregulation of CEBPB and the IL-1/TNF-α/NF-κB pathway independent of the FAB subtype, indicating drug-induced compensatory protection mechanisms. The combination of venetoclax or idasanutlin with inhibitors that block the IL-1/TNF-α pathway demonstrates synergistic cytotoxicity in M4/M5 AML. As such, we uncovered a targetable positive feedback loop that involves CEBPB, IL-1/TNF-α, and monocyte differentiation in M4/M5 leukemia and promotes both intrinsic and extrinsic drug resistance and drug-induced protection against venetoclax and MDM2 inhibitors.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Allen B, Bottomly D, Köhnke T, et al. A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia. Blood. 2025. PMID: 40009487. doi:10.1182/blood.2024028239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。